A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival

S. De Leo
M. Di Stefano
L. Persani
L. Fugazzola
C. Colombo

September 2020

Purpose: Lenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodi...

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Locatelli F. (ORCID:0000-0002-7976-3654)

January 2021

Background: We report results from the phase I dose-finding and phase II expansion part of a multice...

Lenvatinib in the therapy of aggressive thyroid cancer: State of the art and new perspectives with patents recently applied

Silvia M. Ferraria
Ilaria Ruffilli
Marco Centanni
Camilla Virili
Gabriele Materazzi
Magdalini Alexopoulou
Mario Miccoli
Alessandro Antonelli
Poupak Fallahi

January 2018

Abstract: Background and Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor ...

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Schlumberger, Martin
Jarzab, Barbara
Cabanillas, Maria E
Robinson, Bruce
Ball, Douglas W
Mccaffrey, Judith
Newbold, Kate
Allison, Roger
Martins, Renato G
Licitra, Lisa F
Shah, Manisha H
Bodenner, Donald
Elisei, Rossella
Burmeister, Lynn
Funahashi, Yasuhiro
Ren, Min
O'Brien, James P
Sherman, Steven I.
PACINI, FURIO

January 2016

Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer,...

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Cabanillas, Maria E
Schlumberger, Martin
Jarzab, Barbara
Martins, Renato G.
Pacini, Furio
Robinson, Bruce
Mccaffrey, Judith C.
Shah, Manisha H.
Bodenner, Donald L.
Topliss, Duncan
Andresen, Corina
O'Brien, James P.
Ren, Min
Funahashi, Yasuhiro
Allison, Roger
Elisei, Rossella
Newbold, Kate
Licitra, Lisa F.
Sherman, Steven I.
Ball, Douglas W.

January 2015

INTRODUCTION: Positive results of phase 1 studies evaluating lenvatinib in solid tumors includin...

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Cabanillas, Maria E
Schlumberger, Martin
Jarzab, Barbara
Martins, Renato G
Robinson, Bruce
Mccaffrey, Judith C
Shah, Manisha H
Bodenner, Donald L
Topliss, Duncan
Andresen, Corina
O'Brien, James P
Ren, Min
Funahashi, Yasuhiro
Allison, Roger
Elisei, Rossella
Newbold, Kate
Licitra, Lisa F
Sherman, Steven I
Ball, Douglas W.
PACINI, FURIO

January 2015

Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth fa...

Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

Matrone, A
Prete, A
Nervo, A
Ragni, A
Agate, L
Molinaro, E
Giani, C
Valerio, L
Minaldi, E
Piovesan, A
Elisei, R

January 2021

PURPOSE: Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor pro...

Lenvatinib: Role in thyroid cancer and other solid tumors

Cabanillas, Maria E.
Habra, Mouhammed Amir

January 2016

AbstractDespite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor...

Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre

Giani C
Valerio L
Pieruzzi L
Agate L
Viola D
Bottici V
Piaggi P
Lorusso L
Cappagli V
Puleo L
Matrone A
Mazzeo S
Pontillo-Contillo B
Ribechini A
Vitti P
Molinaro E
Elisei R.

January 2018

Objectives: Lenvatinib is an oral multi-thyrosine kinase inhibitor (TKI) approved for the treatment...

Lenvatininb as Treatment for Naïve Patients with Aggressive Thyroid Cancer Bone Metastases and Bad Performance Status

Sonia Garcia-Rodriguez
Guillermo Martinez Pinillos
Manuel Chaves-Conde

January 2020

Lenvatinib is an oral multityrosine kinase inhibitor (TKI) with proven effectiveness in the treatmen...

Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea

신동엽

May 2020

Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment optio...

Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer

Ferrari, Silvia Martina
Elia, Giusy
Ragusa, Francesca
Paparo, Sabrina Rosaria
Mazzi, Valeria
Miccoli, Mario
Galdiero, Maria Rosaria
Varricchi, Gilda
Foddis, Rudy
Guglielmi, Giovanni
Spinelli, Claudio
La Motta, Concettina
Benvenga, Salvatore
Antonelli, Alessandro
Fallahi, Poupak

January 2021

Introduction: Differentiated thyroid cancer (DTC; >90% of all TCs) derives from follicular cells....

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Lorusso, Loredana
Pieruzzi, Letizia
Biagini, Agnese
Sabini, Elena
Valerio, Laura
Giani, Carlotta
Passannanti, PAOLO FRANCESCO
PONTILLO CONTILLO, Benedetta
Battaglia, Valentina
Mazzeo, Salvatore
Molinaro, Eleonora
Elisei, Rossella

January 2016

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular mol...

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

E. V. Borodavina
P. A. Isaev
A. Yu. Shurinov
P. O. Rumyantsev
V. V. Krylov
K. M. Petrosyan
A. D. Kaprin
S. A. Ivanov
S. O. Podvyaznikov
I. S. Romanov
A. M. Mudunov
K. Yu. Slashchuk
R. S. Zhikhorev
M. V. Volkonsky
R. M. Chagova
I. R. Suslova
A. I. Khryapa
A. Kh. Lepshokova
N. L. Fadeeva
A. R. Safarova
L. P. Kaleykina
E. V. Lymar
E. M. Chernyakova
O. A. Snezhko
A. E. Zinkovskaya
F. F. Mufazalov
E. S. Kuzmina
Yu. V. Druzhinina
Sh. I. Musin
M. R. Mukhitova
A. I. Khasanova
S. Z. Safina
S. L. Kirienko

April 2020

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatme...

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.

Taylor, Matthew H
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Dutcus, Corina E
Wu, Jane
Stepan, Daniel E
Shumaker, Robert C
Motzer, Robert J

January 2020

PURPOSE: Modulation of vascular endothelial growth factor-mediated immune suppression via angiogenes...

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival

S. De Leo
M. Di Stefano
L. Persani
L. Fugazzola
C. Colombo

September 2020

Purpose: Lenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodi...

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Locatelli F. (ORCID:0000-0002-7976-3654)

January 2021

Background: We report results from the phase I dose-finding and phase II expansion part of a multice...

Lenvatinib in the therapy of aggressive thyroid cancer: State of the art and new perspectives with patents recently applied

Silvia M. Ferraria
Ilaria Ruffilli
Marco Centanni
Camilla Virili
Gabriele Materazzi
Magdalini Alexopoulou
Mario Miccoli
Alessandro Antonelli
Poupak Fallahi

January 2018

Abstract: Background and Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor ...

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Schlumberger, Martin
Jarzab, Barbara
Cabanillas, Maria E
Robinson, Bruce
Ball, Douglas W
Mccaffrey, Judith
Newbold, Kate
Allison, Roger
Martins, Renato G
Licitra, Lisa F
Shah, Manisha H
Bodenner, Donald
Elisei, Rossella
Burmeister, Lynn
Funahashi, Yasuhiro
Ren, Min
O'Brien, James P
Sherman, Steven I.
PACINI, FURIO

January 2016

Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer,...

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Cabanillas, Maria E
Schlumberger, Martin
Jarzab, Barbara
Martins, Renato G.
Pacini, Furio
Robinson, Bruce
Mccaffrey, Judith C.
Shah, Manisha H.
Bodenner, Donald L.
Topliss, Duncan
Andresen, Corina
O'Brien, James P.
Ren, Min
Funahashi, Yasuhiro
Allison, Roger
Elisei, Rossella
Newbold, Kate
Licitra, Lisa F.
Sherman, Steven I.
Ball, Douglas W.

January 2015

INTRODUCTION: Positive results of phase 1 studies evaluating lenvatinib in solid tumors includin...

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Cabanillas, Maria E
Schlumberger, Martin
Jarzab, Barbara
Martins, Renato G
Robinson, Bruce
Mccaffrey, Judith C
Shah, Manisha H
Bodenner, Donald L
Topliss, Duncan
Andresen, Corina
O'Brien, James P
Ren, Min
Funahashi, Yasuhiro
Allison, Roger
Elisei, Rossella
Newbold, Kate
Licitra, Lisa F
Sherman, Steven I
Ball, Douglas W.
PACINI, FURIO

January 2015

Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth fa...

Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

Matrone, A
Prete, A
Nervo, A
Ragni, A
Agate, L
Molinaro, E
Giani, C
Valerio, L
Minaldi, E
Piovesan, A
Elisei, R

January 2021

PURPOSE: Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor pro...

Lenvatinib: Role in thyroid cancer and other solid tumors

Cabanillas, Maria E.
Habra, Mouhammed Amir

January 2016

AbstractDespite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor...

Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre

Giani C
Valerio L
Pieruzzi L
Agate L
Viola D
Bottici V
Piaggi P
Lorusso L
Cappagli V
Puleo L
Matrone A
Mazzeo S
Pontillo-Contillo B
Ribechini A
Vitti P
Molinaro E
Elisei R.

January 2018

Objectives: Lenvatinib is an oral multi-thyrosine kinase inhibitor (TKI) approved for the treatment...

Lenvatininb as Treatment for Naïve Patients with Aggressive Thyroid Cancer Bone Metastases and Bad Performance Status

Sonia Garcia-Rodriguez
Guillermo Martinez Pinillos
Manuel Chaves-Conde

January 2020

Lenvatinib is an oral multityrosine kinase inhibitor (TKI) with proven effectiveness in the treatmen...

Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea

신동엽

May 2020

Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment optio...

Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer

Ferrari, Silvia Martina
Elia, Giusy
Ragusa, Francesca
Paparo, Sabrina Rosaria
Mazzi, Valeria
Miccoli, Mario
Galdiero, Maria Rosaria
Varricchi, Gilda
Foddis, Rudy
Guglielmi, Giovanni
Spinelli, Claudio
La Motta, Concettina
Benvenga, Salvatore
Antonelli, Alessandro
Fallahi, Poupak

January 2021

Introduction: Differentiated thyroid cancer (DTC; >90% of all TCs) derives from follicular cells....

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Lorusso, Loredana
Pieruzzi, Letizia
Biagini, Agnese
Sabini, Elena
Valerio, Laura
Giani, Carlotta
Passannanti, PAOLO FRANCESCO
PONTILLO CONTILLO, Benedetta
Battaglia, Valentina
Mazzeo, Salvatore
Molinaro, Eleonora
Elisei, Rossella

January 2016

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular mol...

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

E. V. Borodavina
P. A. Isaev
A. Yu. Shurinov
P. O. Rumyantsev
V. V. Krylov
K. M. Petrosyan
A. D. Kaprin
S. A. Ivanov
S. O. Podvyaznikov
I. S. Romanov
A. M. Mudunov
K. Yu. Slashchuk
R. S. Zhikhorev
M. V. Volkonsky
R. M. Chagova
I. R. Suslova
A. I. Khryapa
A. Kh. Lepshokova
N. L. Fadeeva
A. R. Safarova
L. P. Kaleykina
E. V. Lymar
E. M. Chernyakova
O. A. Snezhko
A. E. Zinkovskaya
F. F. Mufazalov
E. S. Kuzmina
Yu. V. Druzhinina
Sh. I. Musin
M. R. Mukhitova
A. I. Khasanova
S. Z. Safina
S. L. Kirienko

April 2020

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatme...

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.

Taylor, Matthew H
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Dutcus, Corina E
Wu, Jane
Stepan, Daniel E
Shumaker, Robert C
Motzer, Robert J

January 2020

PURPOSE: Modulation of vascular endothelial growth factor-mediated immune suppression via angiogenes...

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival

S. De Leo
M. Di Stefano
L. Persani
L. Fugazzola
C. Colombo

September 2020

Purpose: Lenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodi...

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Locatelli F. (ORCID:0000-0002-7976-3654)

January 2021

Background: We report results from the phase I dose-finding and phase II expansion part of a multice...

Lenvatinib in the therapy of aggressive thyroid cancer: State of the art and new perspectives with patents recently applied

Silvia M. Ferraria
Ilaria Ruffilli
Marco Centanni
Camilla Virili
Gabriele Materazzi
Magdalini Alexopoulou
Mario Miccoli
Alessandro Antonelli
Poupak Fallahi

January 2018

Abstract: Background and Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor ...

A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)

Abstract

Extracted data

A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)

Abstract

Extracted data

Related items

Related items